Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pamidronate disodium, quantity: 6 mg/ml - injection, concentrated - excipient ingredients: mannitol; water for injections; sodium hydroxide; phosphoric acid - the treatment of tumour-induced hypercalcaemia. the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. paget's disease of bone.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pamidronate disodium, quantity: 3 mg/ml - injection, concentrated - excipient ingredients: water for injections; phosphoric acid; mannitol; sodium hydroxide - the treatment of tumour-induced hypercalcaemia. the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. paget's disease of bone.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pamidronate disodium, quantity: 3 mg/ml - injection, concentrated - excipient ingredients: mannitol; phosphoric acid; sodium hydroxide; water for injections - the treatment of tumour-induced hypercalcaemia. the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. paget's disease of bone.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pamidronate disodium, quantity: 9 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; mannitol; phosphoric acid - the treatment of tumour-induced hypercalcaemia. paget's disease of bone. the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases or multiple myeloma with bone lesions, in addition to the specific treatment of the tumour. bone metastases and multiple myeloma.

Malta - Inggeris - Medicines Authority

wockhardt uk limited - pamidronate disodium - concentrate for solution for infusion - pamidronate disodium 15 mg/ml - drugs for treatment of bone diseases

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate - solution for infusion - 15 mg/5ml - active: pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate - solution for infusion - 30 mg/10ml - active: pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate - solution for infusion - 60 mg/10ml - active: pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate - solution for infusion - 90 mg/10ml - active: pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

Filipina - Inggeris - FDA (Food And Drug Administration)

hospira philippines, inc. - pamidronate disodium - solution for injection (iv infusion) - 3mg / ml (0.3% w / v)